CAJ | 학술논문

目的观察应用枫香脂联合左旋甲状腺素对分化型甲状腺癌患者术后促甲状腺激素、总体甲状腺激素水平及游离甲状腺素水平的影响.方法分化型甲状腺癌患者采用简单随机化方法分成两组,单纯用药组(n=55,口服左旋甲状腺素片)和联合用药组(n=57,口服枫香脂联合左旋甲状腺素),比较用药前后两组患者血清中促甲状腺素(TSH)、总甲状腺素(T4、T3)和游离甲状腺素(FT3、FT4)的变化.结果联合用药组与单纯用药组相比,两组之间用药前TSH、T4、T3、H4、FT3均没有明显差异,用药后联合用药组的TSH水平明显低于单纯用药组[(0.44±0.10) μIU/ml比(0.94±0.25) μIU/ml,F=12.34,P＜0.05]而FI3升高程度明显高于单纯用药组[(1.08±0.39) pmol/ml比(0.66±0.36) pmol/ml,F=6.9,P＜0.05],差异具有统计学意义.结论枫香脂联合左旋甲状腺素可以在不增加左旋甲状腺素剂量的情况下,提高分化型甲状腺癌患者血清中游离甲状腺素FT3的水平,增强TSH抑制治疗效果.
목적 관찰응용풍향지연합좌선갑상선소대분화형갑상선암환자술후촉갑상선격소、총체갑상선격소수평급유리갑상선소수평적영향.방법 분화형갑상선암환자채용간단수궤화방법분성량조,단순용약조(n=55,구복좌선갑상선소편)화연합용약조(n=57,구복풍향지연합좌선갑상선소),비교용약전후량조환자혈청중촉갑상선소(TSH)、총갑상선소(T4、T3)화유리갑상선소(FT3、FT4)적변화.결과 연합용약조여단순용약조상비,량조지간용약전TSH、T4、T3、H4、FT3균몰유명현차이,용약후연합용약조적TSH수평명현저우단순용약조[(0.44±0.10) μIU/ml비(0.94±0.25) μIU/ml,F=12.34,P＜0.05]이FI3승고정도명현고우단순용약조[(1.08±0.39) pmol/ml비(0.66±0.36) pmol/ml,F=6.9,P＜0.05],차이구유통계학의의.결론 풍향지연합좌선갑상선소가이재불증가좌선갑상선소제량적정황하,제고분화형갑상선암환자혈청중유리갑상선소FT3적수평,증강TSH억제치료효과.
Objective To investigate the therapeutic efficacy of postoperative thryrotropin (thyroid stimulating hormone,TSH) suppressive therapy of liquidambaris resina combined levothyroxine on differential thyroid carcinoma (DTC).Methods Postoperative DTC patients were randomly divided into two groups.57 patients in group A treated with liquidambaris resina combined with levothroxine,while in group B 55 cases treated with levothyroxine alone.Serum level of TSH,T3,T4,FT3 (Free T3),Free T4 (FT4) were determined before and after TSH-suppressive therapy.Results There were no statistical difference in the level of TSH,T4,T3,FT4 and FT3 between the two groups before TSH-suppressive therapy started.But there were statistical difference in the blood concentration of TSH and FT3 between the two groups.The level of TSH in group A was significantly lower than in group B [(0.44 ± 0.10) μIU/ml vs.(0.94 ±0.25) μIU/ml,F =12.34,P ＜ 0.05],and the level of FT3 in group A was significantly higher than in group B [(1.08 ±0.39) pmol/ml vs.(0.66 ±0.36) pmol/ml,F =6.9,P ＜0.05].Conclusions TSH-suppressive therapy with liquidambaris resina combined levothyroxine increases the level of FT3 compared with levothyroxin therapy alone,combined therapy has more powerful TSH-suppressive efficacy in DTC patients.